Latest Pharma Insights
GSK’s Zejula Faces Patent Challenge By Natco In India
GSK’s rising oncology ambitions face headwinds in India, with Natco challenging the validity of the patent underpinning ovarian cancer drug niraparib, seeking that it be quashed.
Scrip - September 30, 2026
GSK’s rising oncology ambitions face headwinds in India, with Natco challenging the validity of the patent underpinning ovarian cancer drug niraparib, seeking that it be quashed.
Scrip - September 30, 2026
Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial
Positive Phase II results for the ILT7-targeting antibody daxdilimab in discoid lupus erythematosus were presented at the EADV meeting. Preparations are underway for registrational studies.
Scrip - September 30, 2026
Positive Phase II results for the ILT7-targeting antibody daxdilimab in discoid lupus erythematosus were presented at the EADV meeting. Preparations are underway for registrational studies.
Scrip - September 30, 2026
Oncology’s Blind Spot: Measuring Tumor Shrinkage, While Patients Die From Metastasis
Oncology drug development is built to reward tumour shrinkage, yet metastasis kills most patients. Closing this blind spot means testing invasion biology and tolerability far earlier.
In Vivo - September 30, 2026
Oncology drug development is built to reward tumour shrinkage, yet metastasis kills most patients. Closing this blind spot means testing invasion biology and tolerability far earlier.
In Vivo - September 30, 2026
Sandoz Aims High To Cement Biosimilars Leadership With ‘Bio100’ Strategy
At its capital markets day at the London Stock Exchange earlier this month, Sandoz set out plans to have 100 biosimilars in its portfolio by 2040, to double its sales between 2025 and 2035, and to invest heavily in biosimilar manufacturing to capture the benefits of vertical integration.
In Vivo - September 30, 2026
At its capital markets day at the London Stock Exchange earlier this month, Sandoz set out plans to have 100 biosimilars in its portfolio by 2040, to double its sales between 2025 and 2035, and to invest heavily in biosimilar manufacturing to capture the benefits of vertical integration.
In Vivo - September 30, 2026
Reorganization Cuts US FDA Chief Counsel Oversight Position At HHS
HHS eliminated the chief counsel for food, research and drugs, which oversaw legal services for FDA and NIH.
HBW Insight - September 30, 2026
HHS eliminated the chief counsel for food, research and drugs, which oversaw legal services for FDA and NIH.
HBW Insight - September 30, 2026
GSK’s Zejula Faces Patent Challenge By Natco In India
GSK’s rising oncology ambitions face headwinds in India, with Natco challenging the validity of the patent underpinning ovarian cancer drug niraparib, seeking that it be quashed.
Scrip - September 30, 2026
GSK’s rising oncology ambitions face headwinds in India, with Natco challenging the validity of the patent underpinning ovarian cancer drug niraparib, seeking that it be quashed.
Scrip - September 30, 2026
Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial
Positive Phase II results for the ILT7-targeting antibody daxdilimab in discoid lupus erythematosus were presented at the EADV meeting. Preparations are underway for registrational studies.
Scrip - September 30, 2026
Positive Phase II results for the ILT7-targeting antibody daxdilimab in discoid lupus erythematosus were presented at the EADV meeting. Preparations are underway for registrational studies.
Scrip - September 30, 2026
Brigham Cardiologist: AI Detection Of Coronary Calcium Could Improve Preventive Care
A randomized trial found AI-informed clinicians initiated or intensified lipid-lowering therapy in 63% of patients at 12 months vs. 19% with standard care. A validation study across 5,468 chest CTs found the Nanox.AI software agreed with expert assessments more than 90% of the time.
Medtech Insight - September 29, 2026
A randomized trial found AI-informed clinicians initiated or intensified lipid-lowering therapy in 63% of patients at 12 months vs. 19% with standard care. A validation study across 5,468 chest CTs found the Nanox.AI software agreed with expert assessments more than 90% of the time.
Medtech Insight - September 29, 2026
EU Puts AI And EHDS At Center Of Cardiovascular Screening Plan
New proposal from the European Commission will require member states to take a personalized, accessible approach to screening to help meet mortality goals.
Medtech Insight - September 29, 2026
New proposal from the European Commission will require member states to take a personalized, accessible approach to screening to help meet mortality goals.
Medtech Insight - September 29, 2026
DOJ Restores FCA Prosecution Guardrails — But Qui Tam Surge May Blunt The Relief
The DOJ has formally restored False Claims Act prosecution guardrails — but the qui tam filing surge heading toward a third record year may limit the practical relief for medtech and other life sciences companies.
Medtech Insight - September 29, 2026
The DOJ has formally restored False Claims Act prosecution guardrails — but the qui tam filing surge heading toward a third record year may limit the practical relief for medtech and other life sciences companies.
Medtech Insight - September 29, 2026
Reorg Cuts US FDA Chief Counsel Oversight Position At HHS
The Health and Human Services Department eliminated the chief counsel for food, research and drugs, which oversaw legal services for the FDA and NIH.
Medtech Insight - September 29, 2026
The Health and Human Services Department eliminated the chief counsel for food, research and drugs, which oversaw legal services for the FDA and NIH.
Medtech Insight - September 29, 2026
Reorganization Cuts US FDA Chief Counsel Oversight Position At HHS
HHS eliminated the chief counsel for food, research and drugs, which oversaw legal services for FDA and NIH.
HBW Insight - September 30, 2026
HHS eliminated the chief counsel for food, research and drugs, which oversaw legal services for FDA and NIH.
HBW Insight - September 30, 2026
Viatris Challenges Another US Wegovy Patent To Resolve Launch Uncertainty
Mylan is challenging another Wegovy patent after Novo Nordisk declined to sue within the statutory 45-day window after a Paragraph IV challenge, seeking to resolve legal uncertainty surrounding its proposed US generic semaglutide product.
Generics Bulletin - September 29, 2026
Mylan is challenging another Wegovy patent after Novo Nordisk declined to sue within the statutory 45-day window after a Paragraph IV challenge, seeking to resolve legal uncertainty surrounding its proposed US generic semaglutide product.
Generics Bulletin - September 29, 2026
Big Win For Prestige Biopharma In Brazil’s Crowded Trastuzumab Biosimilar Market
Even though the trastuzumab biosimilar market is already established in Brazil, the latest Anvisa approval marked an important global expansion milestone for Prestige Biopharma.
Generics Bulletin - September 29, 2026
Even though the trastuzumab biosimilar market is already established in Brazil, the latest Anvisa approval marked an important global expansion milestone for Prestige Biopharma.
Generics Bulletin - September 29, 2026
Oncology’s Blind Spot: Measuring Tumor Shrinkage, While Patients Die From Metastasis
Oncology drug development is built to reward tumour shrinkage, yet metastasis kills most patients. Closing this blind spot means testing invasion biology and tolerability far earlier.
In Vivo - September 30, 2026
Oncology drug development is built to reward tumour shrinkage, yet metastasis kills most patients. Closing this blind spot means testing invasion biology and tolerability far earlier.
In Vivo - September 30, 2026
Sandoz Aims High To Cement Biosimilars Leadership With ‘Bio100’ Strategy
At its capital markets day at the London Stock Exchange earlier this month, Sandoz set out plans to have 100 biosimilars in its portfolio by 2040, to double its sales between 2025 and 2035, and to invest heavily in biosimilar manufacturing to capture the benefits of vertical integration.
In Vivo - September 30, 2026
At its capital markets day at the London Stock Exchange earlier this month, Sandoz set out plans to have 100 biosimilars in its portfolio by 2040, to double its sales between 2025 and 2035, and to invest heavily in biosimilar manufacturing to capture the benefits of vertical integration.
In Vivo - September 30, 2026